$13.630
-0.538 (-3.95%)收盤時
ANL 資訊
ANL 事件
Adlai Nortye Submits CTN for AN4035 Clinical Trial
Adlai Nortye announced that it has submitted a clinical trial notification, or CTN, to Australia's Therapeutic Goods Administration, or TGA, and received approval from the Human Research Ethics Committee, or HREC, to commence its phase I clinical trial evaluating AN4035, a CEACAM5-targeting, pan-RAS inhibitor-based antibody drug conjugate for the treatment of CEACAM5-enriched RAS-addicted solid tumors.
Adlai Nortye Doses First Patient in AN9025 Trial in the US
Adlai Nortye announced that the first patient has been dosed in the United States in the intermittent weekly dosing arm of the ongoing Phase 1 clinical trial of AN9025, a pan-RAS inhibitor.
Adlai Nortye Ltd Trading Halted
Adlai Nortye Ltd (ADR) trading halted, volatility trading pause
Adlai Nortye Files to Sell $600M of Class A Ordinary Shares
Adlai Nortye files to sell $600M of Class A ordinary shares
Adlai Nortye Files to Sell 64.62M Class A Ordinary Shares
Adlai Nortye files to sell 64.62M Class A ordinary shares for holders
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。